BiotechTube

parsaclisib + rituximab + bendamustine + Placebo

Phase 3Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mantle Cell Lymphoma

Conditions

Mantle Cell Lymphoma

Trial Timeline

Mar 11, 2022 → Jul 7, 2034

NCT ID
NCT04849715

About parsaclisib + rituximab + bendamustine + Placebo

parsaclisib + rituximab + bendamustine + Placebo is a phase 3 stage product being developed by Incyte for Mantle Cell Lymphoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04849715. Target conditions include Mantle Cell Lymphoma.

What happened to similar drugs?

1 of 5 similar drugs in Mantle Cell Lymphoma were approved

Approved (1) Terminated (0) Active (4)
✅Acalabrutinib capsuleAstraZenecaApproved
🔄Pirtobrutinib + Ibrutinib + Acalabrutinib + ZanubrutinibEli LillyPhase 3
🔄Rituximab 375 mg/m^2 + Cyclophosphamide 750 mg/m^2 + Doxorubicin 50 mg/m^2 + VELCADE 1.3 mg/m^2 + Prednisone 100 mg/m^2 + Vincristine 1.4 mg/m^2Johnson & JohnsonPhase 3
🔄Acalabrutinib + Bendamustine + Rituximab + PlaceboAstraZenecaPhase 3
🔄Sonrotoclax + Zanubrutinib + PlaceboBeOne MedicinesPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04849715Phase 3Withdrawn

Competing Products

20 competing products in Mantle Cell Lymphoma

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + Brexucabtagene AutoleucelEli LillyPhase 2
42
Obinutuzumab + Glofitamab + PirtobrutinibEli LillyPhase 2
42
enzastaurinEli LillyPhase 2
35
AbemaciclibEli LillyPhase 2
35
Pirtobrutinib + Ibrutinib + Acalabrutinib + ZanubrutinibEli LillyPhase 3
44
Pirtobrutinib + Rituximab + VenetoclaxEli LillyPhase 2
42
Pirtobrutinib and rituximabEli LillyPhase 2
42
gemcitabine + mitoxantrone + rituximabEli LillyPhase 2
35
Rituximab 375 mg/m^2 + Cyclophosphamide 750 mg/m^2 + Doxorubicin 50 mg/m^2 + VELCADE 1.3 mg/m^2 + Prednisone 100 mg/m^2 + Vincristine 1.4 mg/m^2Johnson & JohnsonPhase 3
40
VenetoclaxAbbViePhase 2
35
Ibrutinib + VenetoclaxAbbViePhase 2
35
ABT-199 and Ibrutinib CombinationAbbViePhase 1
29
Venetoclax Oral Tablet [Venclexta]AbbViePhase 2
27
Acalabrutinib capsuleAstraZenecaApproved
43
Acalabrutinib in combination with BR + Acalabrutinib in combination with VRAstraZenecaPhase 1
33
Acalabrutinib + Venetoclax + ObinutuzumabAstraZenecaPhase 1/2
39
Acalabrutinib + R-CHOP standard of care + Acalabrutinib combination with Rituximab + Acalabrutinib monotherapyAstraZenecaPhase 2
42
Acalabrutinib + Venetoclax + RituximabAstraZenecaPhase 2
39
Acalabrutinib + RituximabAstraZenecaPhase 2
42
Acalabrutinib Treatment A + Acalabrutinib Treatment B + Acalabrutinib Treatment C + Acalabrutinib Treatment DAstraZenecaPhase 1
29